Colon Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Silencing of CD133 inhibits GLUT1-mediated glucose transport through downregulation of the HER3/Akt/mTOR pathway in colon cancer.
|
31736063 |
2020 |
Colon Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The results revealed a significant association between Her3 overexpression and tumor differentiation [OR = 2.38; 95% confidence interval (95% CI): 1.76-3.22; P < .001], TNM tumor stage (OR = 0.71; 95% CI: 0.53-0.96; P = .03), and position of colon cancer (OR = 1.71; 95% CI: 1.28-2.27; P < .001).
|
30212974 |
2018 |
Colon Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, our findings suggest that targeting ErbB-3 receptors could represent an effective therapeutic approach in BRAF-V600E mutant colon cancer.
|
26160848 |
2015 |
Colon Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Using a kinome-centered synthetic lethality screen, we find that suppression of the ERBB3 receptor tyrosine kinase sensitizes KRAS mutant lung and colon cancer cells to MEK inhibitors.
|
24685132 |
2014 |
Colon Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results indicate that ERBB3 is a potential target for EGFR- and ERBB2-resistant colon cancer therapy.
|
24970817 |
2014 |
Colon Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, the importance of HER3 in colon cancer and its putative prognostic significance is still unknown.
|
22142822 |
2012 |
Colon Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
ErbB3 expression predicts sensitivity to elisidepsin treatment: in vitro synergism with cisplatin, paclitaxel and gemcitabine in lung, breast and colon cancer cell lines.
|
22485250 |
2012 |
Colon Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Consistent with the mouse data, which suggest that ERBB3-ERBB4 heterodimers contribute to colon cancer survival, experimentally induced loss of ERBB3 in a KRAS mutant human colon cancer cell line was associated with loss of ERBB4 expression, and siRNA knockdown of either ERBB3 or ERBB4 resulted in elevated levels of apoptosis.
|
19690388 |
2009 |
Colon Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
ErbB2 and ErbB3 receptor tyrosine kinases have been associated with the development of human colon cancer, and the expressions of both receptors are high in HT-29 cells.
|
15741050 |
2005 |
Colon Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We previously reported that in the HT29 human colon cancer cell line EGCG, the major biologically active component of green tea, inhibits activation of the RTKs EGFR, HER2, and HER3, and that this is associated with inhibition of multiple downstream signaling pathways.
|
16053920 |
2005 |
Colon Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These findings indicate that erbB2 and erbB3, but not EGFR, may contribute to tumor growth and disease progression in colon cancer.
|
9712416 |
1998 |
Colon Carcinoma
|
0.400 |
CausalMutation
|
disease |
CGI |
|
|
|